WHO COULD BE YOUR NEXT PALEXIA® PR PATIENT?
Palexia® PR starting dose for patients on classic strong opioidse12
*in severe cLBP with a neuropathic pain component, compared to oxycodone/naloxone PR.
#Clinical Studies include: Phase III interventional trials – osteoarthritis knee pain13a; low back pain12a; 1-year safety (osteoarthritis, low back pain)14b; phase IIIb, chronic low back pain with or without a neuropathic component15c; (after conversion from prior WHO step III therapy)1c; chronic osteoarthritis knee pain16c; (after conversion from prior WHO step III therapy)17c. Non-interventional trial: severe chronic pain18d.
a Mean dose during the 12-week maintenance period;
b Mean dose over the 52-week study;
c Mean dose at Week 6 (the first week after titration);
d Mean dose at the final study visit.
e Provided doses ranges are based on information on conversion taken from the individual products’ prescribing information. An equianalgesic ratio for Palexia® PR vs oxycodone CR was derived from clinical phase III trials (tap:oxy ≈ 5:1)5,13 and is in line with equianalgesic information from a phase IIIb trials.14,19
cLBP, chronic lower back pain
CR, controlled release
MOR, µ-opioid-receptor agonist
NRI, noradrenaline reuptake inhibitor
WHO, world health organization